Cho K, Keithly SC, Kurgansky KE, et al. - Considering that mortality in patients with non-severe coronavirus disease 2019 (COVID-19) may reduce in correlation with using early convalescent plasma transfusion, researchers conducted this study emulating a (hypothetical) target trial utilizing observational data from a cohort of United States Veterans admitted to a Department of Veterans Affairs (VA) facility between May 1 and November 17, 2020 with non-severe COVID-19. Convalescent plasma initiated within 2 days of eligibility was the intervention. A total of 4,755 patients contributed to 11,269 eligible person-trials, 402 of which were assigned to the convalescent plasma group. Outcome analysis yielded no meaningful distinctions between non-severe COVID-19 patients treated and untreated with convalescent plasma in terms of 30-day mortality.